[go: up one dir, main page]

WO2008036763A2 - Compositions adhesives pour tissu et methodes associees - Google Patents

Compositions adhesives pour tissu et methodes associees Download PDF

Info

Publication number
WO2008036763A2
WO2008036763A2 PCT/US2007/078932 US2007078932W WO2008036763A2 WO 2008036763 A2 WO2008036763 A2 WO 2008036763A2 US 2007078932 W US2007078932 W US 2007078932W WO 2008036763 A2 WO2008036763 A2 WO 2008036763A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
component
protein
viscosity
aldehyde
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/078932
Other languages
English (en)
Other versions
WO2008036763A3 (fr
Inventor
Glen Gong
Charles Wartchow
Alison Schlosser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PneumRx LLC
Original Assignee
PneumRx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PneumRx LLC filed Critical PneumRx LLC
Priority to EP07842812.5A priority Critical patent/EP2064300A4/fr
Priority to US12/602,468 priority patent/US20100297218A1/en
Priority to JP2009529372A priority patent/JP2010504410A/ja
Publication of WO2008036763A2 publication Critical patent/WO2008036763A2/fr
Publication of WO2008036763A3 publication Critical patent/WO2008036763A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/043—Mixtures of macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A61L24/108—Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
    • C09J189/00—Adhesives based on proteins; Adhesives based on derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2666/00—Composition of polymers characterized by a further compound in the blend, being organic macromolecular compounds, natural resins, waxes or and bituminous materials, non-macromolecular organic substances, inorganic substances or characterized by their function in the composition
    • C08L2666/02—Organic macromolecular compounds, natural resins, waxes or and bituminous materials
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2666/00—Composition of polymers characterized by a further compound in the blend, being organic macromolecular compounds, natural resins, waxes or and bituminous materials, non-macromolecular organic substances, inorganic substances or characterized by their function in the composition
    • C08L2666/02—Organic macromolecular compounds, natural resins, waxes or and bituminous materials
    • C08L2666/26—Natural polymers, natural resins or derivatives thereof according to C08L1/00 - C08L5/00, C08L89/00, C08L93/00, C08L97/00 or C08L99/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/02—Dextran; Derivatives thereof

Definitions

  • the present invention relates to compositions and methods for an adhesive composition
  • the present invention relates to a composition of an adhesive composition containing a protein component and an aldehyde component where the aldehyde component further comprises a thickening agent
  • the adhesive composition is used for adhering to a tissue in various applications
  • Tissue adhesive is another technique used to bond or seal the tissue.
  • Some of the examples of the tissue adhesives include cyanoacrylates, gelatm-formaldehyde compositions, and fibrin based glues Cyanoacrylate adhesive has limited use in the internal applications since the adhesive requires a dry field and is non-absorbable by the tissue The polymerization of the cynoacrylate adhesive on the surface of the tissue may tend to be exothermic and can lead to
  • Fibrin glues use blood products (fibrinogen and co-factors) which can be obtained from multiple human donors
  • Fibrin glues utilize a natural process of blood clot formation to generate an adhesive or sealant composition
  • Fibrin glue is comprised of two components One of the components is a solution of fibrinogen and blood clotting factors such as factor XlII, and the other component is primarily a solution of thrombin and calcium ion Two components are combined to form an artificial blood clot It can therefore present an inherent risk of transmitting diseases to the patient Further, fibrin glues have low strength (generally less than 50 g/cm 2 ) and relatively slow set up time
  • an adhesive composition comprising a protein component having a first viscosity, and an aldehyde component having a second viscosity, where the aldehyde component further comprises a thickening agent
  • the protein component can be derived from a mammalian source
  • the mammalian sources include, for example, human, bovine, bison, ovme, and porcine
  • the protein component can be derived from a recombinant source
  • the protein component is a serum albumin
  • the aldehyde component is, for example, a dialdehyde or a polyaldehyde
  • the dialdehyde is a glutaraldehyde
  • the protein component is a serum albumin and the aldehyde component is a ghitaraldehyde
  • the protein component can comprise more than 15% protein monomer
  • the thickening include, for example, human, bovine, bison, ovme, and porcine
  • the protein component can be derived from
  • radiopaque material includes, for example, bismuth oxide (Bi 2 O 3 ), zinc oxide (ZnO), barium sulfate (BaSO 4 ) lanthanum oxide (La 2 O 3 ), cerium oxide (CeO 2 ), terbium oxide, ytterbium oxide, neodymium oxide, zircoma (ZrO 2 ), strontia (SrO), tin oxide (SnO 2 ), radiopaque glass and silicate glass
  • the radioopaque glass includes, for example, barium silicate, silico-alumino barium or strontium containing glass
  • the silicate glass includes, for example, barium or strontium containing glass
  • an adhesive composition comprising a protein component having a first viscosity, and an aldehyde component having a second viscosity, where the composition comprises between about 1-26% protein concentration
  • the protein component can comprise between about 1-75% protein concentration
  • the protein component is a serum albumin
  • the protein component and the aldehyde component are present in a ratio of from 6 1 to 1 6
  • the protein component and the aldehyde component are present in the ratio of 1 1
  • the protein component can also comprise more than 15% protein monomer
  • Another aspect of the present invention relates to an adhesive composition
  • an adhesive composition comprising a mixture of a serum albumin component having a first viscosity, and an aldehyde component having a second viscosity, wherein the composition comprises between about 1-26% of the serum albumin concentration
  • the serum albumin component is derived from porcme
  • the aldehyde component is a glutaraldehyde.
  • the aldehyde composition further comprises a thickening agent
  • the thickening agent includes, for example, dextran, polyethylene glycol or carboxymethyl cellulose
  • the second viscosity of the aldehyde component approximates the first viscosity of the serum albumin component
  • the serum albumin component comprises between about 1-75% serum albumin concentration
  • the serum albumin component and the aldehyde component are present in a ratio of from 6 1 to 1 6
  • the protein component can also comprise more than 15% protein monomer
  • Yet another aspect of the present invention relates to a method for causing adhesion of tissue, comprising mixing a first composition comprising a protein component having a first viscosity with a second composition comprising an aldehyde component having a second viscosity to obtain an adhesive composition and adjusting the second viscosity of the second composition with a thickening agent, introducing the adhesive composition to a tissue, and allowing the adhesive composition to adhere to the tissue
  • the protein component is derived from porcine
  • the protein component is a serum albumin
  • the aldehyde component is a dialdehyde or a polyaldehyde
  • the aldehyde component is a glutaraldehyde
  • the protein component is a serum albumin and the aldehyde component is a glutaraldehyde
  • the first viscosity approximates the second viscosity
  • the first viscosity approximates the second viscosity
  • the first viscosity approximates the second visco
  • radiopaque material includes, for example, bismuth oxide (Bi 2 O 3 ), zinc oxide (ZnO), ba ⁇ um sulfate (BaSO 4 ) lanthanum oxide (La 2 O 3 ), cerium oxide (CeO 2 ), terbium oxide, ytterbium oxide, neodymium oxide, zirconia (ZrO 2 ), strontia (SrO), tin oxide (SnO 2 ), radiopaque glass and silicate glass
  • the radioopaque glass includes, for example, ba ⁇ um silicate, silico-alurmno barium or strontium containing glass
  • the silicate glass includes, for example, barium or strontium containing glass
  • Another aspect of the present invention relates to a method for marking a location withm the human body, comprising providing a first component comprising a protein having a first viscosity and a second component comprising an aldehyde having a second viscosity, mixing the first component with the second component resulting in a target composition, introducing the target composition to a location, and marking a site of the location with the target composition
  • the target composition is a palpable material
  • the protein is a serum albumin derived from porcine
  • the aldehyde is a glutaraldehyde
  • the first viscosity of the first component or the second viscosity of the second component is altered prior to the mixing step
  • Yet another aspect of the present invention relates to a process of making an adhesive composition, comprising providing a first protein component with a first viscosity, providing a second aldehyde component with a second viscosity, adjusting the first viscosity, the second viscosity or both, and mixing the first component with the second component to obtain an adhesive composition
  • the protein component is a serum albumin derived from porcine
  • the aldehyde component is a glutaraldehyde
  • the first viscosity of the first component approximates the second viscosity of the second component
  • FIG. 1 is a flow chart depicting some of the embodiments of the compositions and methods as provide herein, and
  • FIGS. 2A-B illustrate a delivery device with a dual chamber for holding the protein component and the aldehyde component prior to delivery, and a delivery cannula
  • FIG. 2B illustrates the mixing chamber and delivery trocar of the device DETAILED DESCRIPTION OF THE INVENTION
  • the adhesive composition comprises of a protein component and an aldehyde component wherein the aldehyde component further comprises of a thickening agent
  • Any component of the composition can be a percentage of the composition assessed by weight, weight-to-weight, weight-to-volume, or volume-to-volume
  • a protein component may be provided A thickening agent may be added to the aldehyde component and the aldehyde component may then be provided The protein component and the aldehyde component may be mixed to obtain an adhesive composition The adhesive composition may be then introduced to a tissue The adhesive composition may be allowed to cure and adhere to the tissue
  • the steps can be performed in other alternate orders and/or one or more steps may be skipped
  • the thickening agent may be added to the aldehyde component and the aldehyde component may be provided A protein component may then be provided The aldehyde component and the protein component are then mixed to obtain an adhesive composition
  • the protein component and the aldehyde component may be introduced directly to the tissue such that the adhesive composition is formed on the surface of the tissue
  • a Protein component in the adhesive composition is a Protein component in the adhesive composition
  • the protein component m the adhesive composition can be obtained from various mammalian sources, such as, for example, human, bovine (genus bos), bison (genus bison), ovine (genus ovis), porcine (genus sus), or other vertebrates
  • the protein component can be derived from a recombinant source such as, plant, non-animal source, bacteria (e g , E coll), yeast (e g , Pichia pasto ⁇ s, and Saccharomyces cerevisiae), mammalian cell, insect cell expression vector system, transgenic animals, etc
  • the protein component in the adhesive composition as provided herein is derived from a porcine source
  • the porcine source may not be infected with bacteria or viruses found in humans and other animals
  • human blood can be infected with HIV and bovine blood can be infected with bacterial and viral impurities
  • the porcine source can provide a safe and non-toxic source of protein for the adhesive
  • the genus mammalian source as provided above can include the entire sub genus and species that fall within the respective genus
  • the genus sus includes all the species that fall withm the genus sus
  • the species of the genus sus include, but are not limited to, Sus barbatus, Sus bucculentus, Sus cebifrons, Sus celebensis, Sus daelius, Sus zzim, Sus philippensis, Sus salvanius, Sus scrofa, Sus timo ⁇ ensis, Sus verrucosus, and Sushongoncosus
  • the genus bos includes, but is not limited to, subgenus bos including bos taurus and bos aegyptiacus, subgenus bibos including bos frontalis and bos javanicus, subgenus novibos including bos sauveh, and, subgenus poe
  • the protem component m the adhesive composition can be derived from blood plasma or serum of any of the mammalian sources
  • the techniques for deriving the protein component from blood plasma or serum include, but are not limited to, drying, evaporation, precipitation, amplification, fractionation, heat shock, reverse osmosis, nanofiltration, ultrafiltration, microfiltration, sedimentation, centrifugation, electrodialysis, dilution, adjustment of pH, addition of preservatives and cahbrants, addition of denaturants, desalting of samples, concentration, extraction and purification.
  • the protein component can be prepared and/or purified by techniques such as, ion exchange chromatography, high-performance liquid chromatography (HPLC), size exclusion chromatography (SEC), mass spectrometry (MS), metal ion affinity chromatography, gel filtration, hydrophobic chromatography, chromatofocusing, adsorption chromatography, isoelectric focusing and the like After purification, the protein component can be further analyzed for properties such as, viscosity, and osmolality. It shall be understood that methods for deriving, purifying and/or analyzing the protein component are known in the art and are withm the scope of the present invention
  • the protein component as provided herein can comprise a purified protein or a mixture of proteins
  • the protein component may comprise a mixture of monomenc, dime ⁇ c, and/or polymeric protein contents
  • the protein component may further comprise other plasma proteins, endotoxins, metal ions, or albumin aggregates
  • the protein component in the adhesive composition is substantially free of dimeric proteins, polymeric proteins, other plasma proteins, endotoxins, metal ions, albumin aggregates or any decomposed matters
  • the protem component substantially consists of a protem with high monomer content.
  • the protein component of an adhesive composition can itself be further comprised of components and/or sub-components
  • the protem component can be described in terms of weight, weight-to- weight, weight-to- volume, or volume-to-volume, either before or after mixing
  • the protein component comprises at least about 50% monomenc protein; at least about 55% monomenc protein, at least about 60% monomenc protem, at least about 70% monomenc protem, at least about 80% monomenc protem; at least about 85% monomenc protem; at least about 90% monomeric protein; at least about 95% monomenc protein; at least about 99% monomenc protem; or at least about 99.99% monomenc protein
  • the protein component comprises at least about 50% monomeric protein.
  • the protem component comprises at least about 90% monomenc protein
  • the protein in the protein component can be a human or animal-derived serum albumin, or ovalalbumin.
  • the protem can also be a commercial plasma extender such as Plasma-Plex or Plasmanate which may contain reconstituted solutions of about 5% plasma protein by weight or other appropriate solutions.
  • the protem in the protem component is serum albumin derived from a porcine source
  • the protein component can comprise about 1-90% protein concentration In some embodiments, the protein component comprises of about 1-75% protein concentration. In some embodiments, the protem component comprises of about 5-75% protein concentration, about 10-75% protem concentration, about 20-75% protem concentration, about 30-75% protein concentration, about 40-75% protein concentration, about 50-75% protein concentration; or about 60-75% protein concentration
  • the adhesive composition as provided herein can comprise a low protein concentration
  • the low protein concentration can reduce the toxicity of the adhesive composition in the human or animal body
  • the adhesive composition comprises at least about 1% protein concentration, at least about 5% protein concentration, at least about 8% protem concentration, at least about 10% protem concentration, at least about 12% protein concentration; at least about 15% protein concentration; at least about 18% protein concentration; at least about 20% protein concentration, at least about 22% protein concentration; at least about 24% protein concentration; at least about 26% protein concentration; or at least about 30% protein concentration.
  • the adhesive composition comprises about 1-26%, about 5-20%, or about 10-20% protein concentration.
  • the adhesive composition comprises at least about 1% serum albumin concentration; at least about 5% serum albumin concentration; at least about 8% serum albumin concentration; at least about 10% serum albumin concentration; at least about 12% serum albumin concentration; at least about 15% serum albumin concentration; at least about 18% serum albumin concentration; at least about 20% serum albumin concentration; at least about 22% serum albumin concentration; at least about 24% serum albumin concentration; at least about 26% serum albumin concentration; or at least about 30% serum albumin concentration.
  • the adhesive composition comprises about 1-26%, about 5-20%, or about 10-20% of the serum albumin concentration.
  • the aldehyde component in the adhesive composition as provided herein can be any biocompatible aldehyde with low toxicity.
  • the aldehyde component includes a di-aldehyde, a polyaldehyde or a mixture thereof
  • the examples of the aldehyde include, but are not limited to, glyoxal, chondroitin sulfate aldehyde, succmaldehyde, glutaraldehyde, and malealdehyde.
  • the aldehyde component is glutaraldehyde.
  • aldehydes which have low toxicity include multifunctional aldehydes derived from naturally-occurring substances, e g., dextrandialdehyde, or saccha ⁇ des
  • the aldehyde component can be an aldehyde product obtained by an oxidative cleavage of carbohydrates and their derivatives with penodate, ozone or the like.
  • the aldehyde may optionally be pre-treated with heat See US 2004/0081676 by Schankereli for Biocompatible phase mvertable proteinaceous compositions and methods for making and using the same.
  • the aldehyde component can be analyzed for properties such as, viscosity, and osmolality.
  • the aldehyde component of an adhesive composition can itself be further comprised of components and/or sub-components.
  • the aldehyde component can be described in terms of weight, weight-to- weight, weight-to- volume, or volume-to-volume, either before or after mixing.
  • the aldehyde component comprises of about 1-90% aldehyde concentration. In some embodiments, the aldehyde component comprises of about 1-75% aldehyde concentration. In some embodiments, the aldehyde component comp ⁇ ses of about 5-75% aldehyde concentration; about 10-75% aldehyde concentration; about 20-75% aldehyde concentration; about 30-75% aldehyde concentration; about 40-75% aldehyde concentration; about 50-75% aldehyde concentration; or about 60-75% aldehyde concentration.
  • the adhesive composition can comprise at least about 1% aldehyde concentration; at least about 5% aldehyde concentration; at least about 10% aldehyde concentration; at least about 20% aldehyde concentration; at least about 30% aldehyde concentration; at least about 40% aldehyde concentration; at least about 50% aldehyde concentration; at least about 60% aldehyde concentration, at least about 70% aldehyde concentration; at least about 80% aldehyde concentration; at least about 90% aldehyde concentration, or at least about 99% aldehyde concentration.
  • the adhesive composition comp ⁇ ses of about 1-30%, about 25-75%, about 50-75% or about 75-99% aldehyde concentration
  • the adhesive composition comprises of at least about 1% glutaraldehyde concentration; at least about 5% glutaraldehyde concentration, at least about 8% glutaraldehyde concentration; at least about 10% glutaraldehyde concentration; at least about 20% glutaraldehyde concentration; at least about 30% glutaraldehyde concentration; at least about 40% glutaraldehyde concentration, at least about 50% glutaraldehyde concentration; at least about 60% glutaraldehyde concentration; at least about 70% glutaraldehyde concentration, at least about 80% glutaraldehyde concentration, at least about 90% glutaraldehyde concentration, or at least about
  • the adhesive composition comprises about 1-30%, about 25-75%, about 50-75% or about 75-99% glutaraldehyde concentration
  • the adhesive composition of the present invention can further comprise a thickening agent
  • a thickening agent include, but are not limited to, dextran, carboxymethyl cellulose, polyethylene glycol, liposomes, prohposomes, glycerol, starch, carbohydrates, povidone, polyethylene oxide, and polyvinyl alcohol
  • the thickening agent is dextran
  • the thickening agent can be added to the aldehyde component before the aldehyde component is mixed with the protein component to make the adhesive composition
  • the thickening agent can alter the viscosity of the aldehyde component and thereby alter the gel time of the adhesive composition
  • Alteration of the viscosity of the aldehyde component includes any modification of the viscosity of the composition
  • Alteration of the gel time of the aldehyde component includes any modification of the gel time of the composition
  • alteration includes increase or decrease m the gel time of the adhesive composition
  • the gelling of the adhesive composition includes a substantial increase in a viscosity that can be measured using a rheometer or viscometer instrument
  • the increase m the viscosity includes transition from a fluid state to a solid or tmcksotropic state
  • the thickening agent can increase the viscosity of the aldehyde component and hence, decrease the gel time of the adhesive composition
  • the aldehyde component comprises at least about 0 5% thickening agent, at least about 2% thickening agent, at least about 5% thickening agent, at least about 10% thickening agent, at least about 20% thickening agent, at least about 30% thickening agent, at least about 40% thickening agent, at least about 50% thickening agent, at least about 60% thickening agent, at least about 70% thickening agent, at least about 80% thickemng agent, or at least about 90% thickening agent
  • the adhesive composition can comprise at least about 0 5% of the thickening agent
  • the adhesive composition comprises at least about 1% thickening agent concentration, at least about 5% thickening agent concentration, at least about 10% thickening agent concentration, at least about 20% thickening agent concentration, at least about 30% thickemng agent concentration, at least about 40% thickening agent concentration, at least about 50% thickening agent concentration, at least about 60% thickening agent concentration, at least about 70% thickening agent concentration, at least about 80% thickemng agent concentration, or at least about 90% thickening agent concentration
  • the adhesive composition comprises at least about 0 5%- 10%, at least about 0 5%-25%, or at least about 0 5%-50% thickening agent concentration
  • the amount of thickening agent added to the aldehyde component can be varied depending on the desired increase in the viscosity of the aldehyde component
  • the thickening agent increases the viscosity of the aldehyde component such that the viscosity of the aldehyde component matches or approximates the viscosity of the protein component. Such matching of the aldehyde component viscosity with the protein component viscosity can enhance the mixing efficiency of the two components in the process of making the adhesive composition.
  • the thickening agent increases the viscosity of the aldehyde component by at least about 5%. In some embodiments, the thickening agent increases the viscosity of the aldehyde component by at least about 8%; at least about 10%; at least about 15%; at least about 20%; at least about 25%; at least about 30%; at least about 40%; at least about 50%; at least about 60%; at least about 70%; at least about 80%; or at least about 90%.
  • the thinning agent can be added to the protein component before the protein component is mixed with the aldehyde component to make the adhesive composition. The thinning agent can alter the viscosity of the protein component and thereby alter the gel time of the adhesive composition.
  • the thinning agent can decrease the viscosity of the protein component and hence, increase the gel time of the adhesive composition.
  • the amount of thinning agent added to the protein component can be varied depending on the gel time needed for the adhesive composition. For example, if a longer gel time (such as, few minutes to hours) is desired for the adhesive composition then a higher amount of thinning agent may be added to the protein component. Alternatively, if a shorter gel time (such as, less than a minute) is needed for the adhesive composition then a lower amount of thinning agent may be added to the protein component.
  • a shorter gel time such as, less than a minute
  • the protein component comprises at least about 0.5% thinning agent; at least about 2% thinning agent; at least about 5% thinning agent; at least about 10% thinning agent; at least about 20% thinning agent; at least about 30% thinning agent; at least about 40% thinning agent; at least about 50% thinning agent; at least about 60% thinning agent; at least about 70% thinning agent; at least about 80% thinning agent; or at least about 90% thinning agent.
  • the adhesive composition can comprise at least about 0.5% of the thinning agent
  • the adhesive composition comprises at least about 1% thinning agent; at least about 5% thinning agent; at least about 10% thinning agent; at least about 20% thinning agent; at least about 30% thinning agent; at least about 40% thinning agent; at least about 50% thinning agent; at least about 60% thinning agent; at least about 70% thinning agent; at least about 80% thinning agent; or at least about 90% thinning agent.
  • the adhesive composition comprises at least about 0.5%-10%, at least about 0.5%-25%, or at least about 0 5%-50% thinning agent
  • the amount of thinning agent added to the protein component can be varied depending on the desired decrease m the viscosity of the protein component.
  • the thinning agent decreases the viscosity of the protein component such that the viscosity of the protein component matches or approximates the viscosity of the aldehyde component. Such matching of the aldehyde component viscosity with the protein component viscosity can enhance the mixing efficiency of the two components in the process of making the adhesive composition.
  • the thinning agent decreases the viscosity of the protein component by at least about 5%.
  • the thinning agent decreases the viscosity of the protein component by at least about 8%; at least about 10%; at least about 15%; at least about 20%; at least about 25%; at least about 30%; at least about 40%; at least about 50%; at least about 60%, at least about 70%; at least about 80%; or at least about 90%.
  • the adhesive composition as provided herein can optionally contain other additives. These additives may be added to the protein component or the aldehyde component prior to their mixing Alternatively, these materials may be added to the adhesive composition after the mixing of the protein component and the aldehyde component.
  • the adhesive composition optionally comprises a radiopaque material.
  • the examples of the radiopaque material include, but are not limited to, heavy metals, oxides, sulfates, ceramics and fluorides that are not hazardous such as bismuth oxide (B1 2 O 3 ), zinc oxide (ZnO), barium sulfate (BaSC ⁇ ) lanthanum oxide (La 2 O 3 ), cerium oxide (Ce ⁇ 2 ), terbium oxide, ytterbium oxide, neodymium oxide, zirconia (ZrO 2 ), strontia (SrO) 3 tin oxide (SnO 2 ), and radiopaque glasses such as barium silicate, silico-alumino barium or strontium containing glasses and silicate glasses containing barium or strontium.
  • the radioopaque material comprises at least about 0.001%; at least about 0.05%; at least about 0.1%; at least about 0.2%; at least about 0.5%; at least about 1%; at least about 2%; at least about 5%; at least about 8%; or at least about 10% of the adhesive composition.
  • the adhesive composition as provided herein can optionally contain additives such as, but not limited to, water, buffer, saline solution, neutral salt, carbohydrate, fiber, miscellaneous biological material, wetting agent, antibiotics, preservative, dye, chitosans, thickening agent, thinning agent, fibrinogen, polymer such as polyethylene glycol or combination thereof.
  • additives such as, but not limited to, water, buffer, saline solution, neutral salt, carbohydrate, fiber, miscellaneous biological material, wetting agent, antibiotics, preservative, dye, chitosans, thickening agent, thinning agent, fibrinogen, polymer such as polyethylene glycol or combination thereof.
  • Polymers include synthetic polymers such as, polyamides, polyesters, polystyrenes, polyacrylates, vinyl polymers (e.g., polyethylene, polytetrafluoro-ethylene, polypropylene and polyvinyl chloride), polycarbonates, polyurethanes, poly dimethyl siloxanes, cellulose acetates, polymethyl methacrylates, ethylene vinyl acetates, polysulfones, nitrocelluloses and similar copolymers.
  • Polymers further include biological polymers which can be naturally occurring or produced in vitro by fermentation and the like.
  • Biological polymers include, without limitation, collagen, elastin, silk, keratin, gelatin, polyamino acids, polysaccharides (e.g., cellulose and starch) and copolymers thereof.
  • Flexibilizers can be included in the adhesive composition to provide flexibility to the adhesive bond upon curing. Flexibilizers maybe naturally occuring compositions. Suitable flexiblizers include synthetic and natural rubbers, synthetic polymers, natural non-native biocompatible proteins (such as exogenous (i.e., non-native) collagen and the like), glycosaminoglycans (GAGs) (such as haluronin and chondroitin sulfate), and blood components (such as fibrin, fibrinogen, albumin and other blood factors).
  • GAGs glycosaminoglycans
  • blood components such as fibrin, fibrinogen, albumin and other blood factors.
  • the adhesive composition as provided herein can optionally include salts and/or buffers.
  • the salt include, but are not limited to, sodium chloride, potassium chloride and the like.
  • Suitable buffers can include, for example, ammonium, phosphate, borate, bicarbonate, carbonate, cacodylate, citrate, and other organic buffers such as tris(hydroxymethyl) aminomethane (TRIS), morpholine propanesulphonic acid (MOPS), and N-(2- hydroxyethyl) piperazine-N'(2-ethanesulfonic acid) (HEPES).
  • Suitable buffers can be chosen based on the desired pH range for the adhesive composition.
  • Additional additives may be present in the adhesive composition to modify the mechanical properties of the composition.
  • Some additives include, for example, fillers, softening agents and stabilizers.
  • fillers include, but are not limited to, carbon black, metal oxides, silicates, acrylic resin powder, and various ceramic powders.
  • softening agents include, but are not limited to, dibutyl phosphate, dioctylphosphate, tricresylphosphate, tributoxyethyl phosphates and other esters.
  • stabilizers include, but are not limited to, trimethyldihydroquinone, phenyl- ⁇ -naphthyl amine, p-isopropoxydiphenylamine, diphenyl-p-phenylene diamine and the like.
  • Another aspect of the present invention relates to a process of making the adhesive composition by mixing the protein component and the aldehyde component to obtain an adhesive composition.
  • a thickening agent is added to the aldehyde component prior to mixing of the aldehyde component with the protein component.
  • a thinning agent is added to the protein component prior to mixing of the protein component with the aldehyde component.
  • the protein component and the aldehyde component are present in the adhesive composition in a ratio of from 6: 1 to 1 :6. In some embodiments, the protein component and the aldehyde component are present in a ratio of 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, or 1 :6. In some embodiments, the protein component and the aldehyde component are present in a ratio of 1 : 1.
  • the serum albumin component and the aldehyde component can be present in the adhesive composition in a ratio of from 6:1 to 1:6. In some embodiments, the serum albumin component and the aldehyde component are present in a ratio of 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, or 1:6. In some embodiments, the serum albumin component and the aldehyde component are present in a ratio of 1 : 1.
  • the protein component, aldehyde component, and thickening agent/thinning agent can be filled in a separate container such as vial or syringe etc.
  • the protein component, aldehyde component, and thickening agent/thinning agent can then be mixed according to the invention, just prior to the use.
  • the thickening agent can be mixed with the aldehyde component before filling the aldehyde component in the container.
  • the protein component, aldehyde component, and thickening agent/thinning agent can be mixed to make the adhesive composition and the adhesive composition can be filled into the container.
  • each of the protein component, aldehyde component and thickening agent/thinning agent can be mixed separately with suitable additives and then separately filled in the container.
  • suitable additives can also be added to the adhesive composition before filling the adhesive composition into the container.
  • the container can be filled in the aseptic conditions.
  • the solutions can also be sterilized after filling.
  • the solution of the protein component, aldehyde component, thickening agent, or thinning agent can be lyophilized.
  • the lyophilized protein component, aldehyde component, thickening agent, or thinning agent can be reconstituted with water or saline just prior to use.
  • the solution of the adhesive composition can be lyophilized.
  • the lyophilized adhesive composition can be reconstituted with water or saline just prior to use.
  • the protein component, aldehyde component, thickening agent, thinning agent or the adhesive composition may be filled in the container and sealed with packaging materials which may not allow transmission of oxygen.
  • the user mixes the components to form the desired composition.
  • Another aspect of the invention relates to introducing an adhesive composition at a target, or selected, location within the body, such as on tissue, organ, organ component, or cavernous component of an organism such that the adhesive composition adheres to the tissue, organ, organ component, or cavernous component.
  • the present invention relates to a method for causing adhesion of tissue by mixing the protein component with the aldehyde component; adjusting the viscosity of the aldehyde component with a thickening agent; introducing the adhesive composition to a tissue; and allowing the adhesive composition to adhere to the tissue.
  • the protein component and the aldehyde component are allowed to react on one or more surfaces of the tissue to be bonded.
  • the adhesion can be rapid and can take place in less than a minute, such as 10-20 seconds. In some embodiments, the adhesion of the adhesive composition may take place from 1-10 minutes, lOminutes-lhr, or l-5hr.
  • the gel time of the adhesive composition can be optimized by altering the viscosity of the aldehyde component using the thickening agent. Alternatively, the gel time can be optimized by altering the viscosity of the protein component by using the thinning agent.
  • the gel time of the adhesive compositions as provided herein can also be optimized by use of buffers having different pH values or buffers having different iomc strengths
  • the adhesion composition of the invention can provide bond/tear strength of about 300-1500 g/cm 2
  • the bond/tear strength and the gel time can be varied depending on the variables such as temperature, pH, viscosity of the protein component, viscosity of the aldehyde component or the like
  • the adhesive composition of the present invention can provide strong and rapid bonding to a wide range of substrates of natural or synthetic origin, providing a broad range of possible applications
  • the adhesive composition of present invention can bond to living tissues, including muscle, skm, connective tissue, nerve tissue, vascular and cardiac tissues, adipose tissue, cartilage, bone, and the like.
  • the adhesive composition can bond to corresponding cadaver tissues, which may be preserved or otherwise chemically treated
  • the adhesive composition can also bond to natural or synthetic mate ⁇ als such as, leather, rubber, Dacron®, or Teflon®, as well as to metals [0067]
  • the adhesive composition as provided herein can be used for the attachment of surgical grafts and devices, wound closure, trauma repair, hemostasis, and the like in the practice of human or veterinary medicine Non medical applications of the adhesive are also anticipated
  • the adhesive composition may be used to bind tissue together either as an adjunct to or as a replacement of sutures, staples, tapes and/or bandages
  • the adhesive composition as provided herein may be used to prevent post-surgical adhesions
  • the adhesive composition can be applied and cured as a layer on surfaces of internal organs or tissues in order to prevent the formation of adhesions at a surgical site as the site heals
  • Additional applications of the subject adhesive composition include sealing tissues to prevent or control blood or other fluid leaks at suture or staple lines as well
  • the adhesive composition can be used to stop a hemorrhage in general surgery, reconstruct nerve ruptures in neurosurgery, adhere skin and cartilage transplants and defects in plastic surgery, treat pneumothorax and/or fistulas in general or thoracic surgery, and support vascular and intestinal anastomoses in vascular and general surgery
  • the subject adhesive composition can be used in the treatment of chondral and osteochondral fractures, transplantation of chondral or osteochondral materials, treatment of osteochondritis dissecans, joint fractures, meniscal tears as well as ruptured ligaments, tendons, myotendmeous junctions or muscles, cartilage transplantation, bone transplantation, ligament transplantation, tendon transplantation, chondral transplantation, chondro-osseous transplantation, osseous transplantation, skm graft fixation, grafting (repairing) nerves and blood vessels, patching vascular grafts, microvascular blood vessel anastomosis, and treatment of combinations of the tissue surfaces Furthermore
  • the adhesive composition can be used in surgical settings such as, operating rooms, emergency rooms and the like
  • the physician for example, can use the adhesive composition for implanting prosthesis or for adhering a patients' native tissue to itself.
  • the adhesive composition can also be used in manufacturing settings Manufacturing settings can include settings where medical devices are assembled For example, m a heart valve prosthesis, one or more of the heart valve leaflets can be associated with the support structure by the subject adhesive composition
  • the adhesive composition can be applied to a supporting structure such as a stent or a conduit that supports prosthesis.
  • the invention provides a method of marking a location within the human or animal body by providing the subject adhesive composition to a site of the location withm the human body and thereby marking the location.
  • the subject adhesive composition can be used to mark a tissue/biopsy site for malignant, benign, or other lesions
  • physicians obtain a tissue specimen or sample from a lesion, suspicious site, organ, etc for pathological examination and analysis, in order to diagnose and treat medical conditions.
  • Tissue samples may be taken during exploratory or typical open surgery procedures
  • the tissue samples can be taken percutaneously or endoscopically during biopsy or surgical procedures
  • it can take several days to weeks, following tissue sampling, to compile the results of pathologic examination and testing and to determine an appropriate medical treatment before the surgery or biopsy
  • It can be difficult for the physician, surgeon, or clinician to locate the site of the lesion again, in order to perform subsequent therapy To execute the required treatment the site where the sample(s) is taken needs to be accurately located.
  • the subject adhesive composition marks a site of the lesion in the human or animal body by adhering to the tissue at the site of the lesion
  • the adhesive composition polymerizes into a palpable material Since the subject adhesive composition adheres to the tissue and then polymerizes in situ, it does not move away from the lesion site.
  • the physician, surgeon, or clinician can then locate the site of the lesion by the touching, or palpating, the region
  • the polymerized material unlike the lesion itself, is perceivable by touch and therefore locatable by the physician, surgeon or clinician. Once the physician locates the lesion using palpation, surgical excision of the lesion can be performed with the least amount of collateral tissue damage
  • the polymerized adhesive composition can be adsorbed slowly by the tissue by hydrolysis.
  • the adhesive composition of the present invention may be applied to tissue in a number of different ways
  • the protein component and the aldehyde component may be mixed together and then applied using common applicators
  • the two components may be mixed together and then applied as spray.
  • the adhesive may be applied using a delivery device as shown in FIG. 2A-B (US Application No 2006/0025815 to McGurk et al for Lung Device With Sealing Features).
  • FIG. 2A-B US Application No 2006/0025815 to McGurk et al for Lung Device With Sealing Features.
  • each chamber can comprise a component of the adhesive composition
  • the components of the adhesive composition can be delivered down the separate channels of the device 900.
  • a plunger 908 is provided to advance the components down each chamber of the delivery housing
  • the protein component and the aldehyde component are advanced through separate sealed tips 910, 910' in order to facilitate easy replacing of the stir chamber 920 in the event of a clog
  • the adhesive delivery housing 901 is easily separable from the stir chamber 920 to facilitate replacement during a procedure
  • the stir chamber 920 receives the protein component and the aldehyde component from at least two ports of the adhesive delivery housing
  • Mixing elements or baffles 922 are provided to mix the components together as the components advance down the stir chamber 920
  • the mixing chamber can have prongs that interact with tips to break its seals when the mixing chamber is connected to the device
  • the distal end of the stir chamber 920 features a porous plug filter 924 that enables air to escape the stir chamber 920 through an air bleed hole 926 located on the side of the strr chamber 920 at its distal end
  • Suitable filters include microfilters available from GenProbe The filter properties are such that air can be dispersed through the filter transverse to the axis of the adhesive while the adhesive will be forced axially through the filter
  • FIG. 2B illustrates another delivery device having a plunger 950 advancing adhesive 952 through a chamber while air 953 is advanced through a porous plug filter 924 where it can exit through the air bleed hole 926 before the adhesive is delivered through the cannula into the target tissue
  • the user deliver the tip of the delivery device to a target location withm a patient, the user activates the mixing feature (e g , by pressing the plunger) to begin mixing the components, the composition (i e , the mixed components) is then delivered to the target location
  • the mixing feature e g , by pressing the plunger
  • a sealant composition was prepared comprising 40% albumin and 0 5% chitosan and a crosslinker solution containing 7 5% heat-processed glutaraldehyde and 20% dextran
  • the process followed for making the sealant was as described above
  • the lungs of an anaesthetized pig were exposed and deflated Following this step, a portion of the upper lobe of the lung was transected and the cut site of the deflated lung was sealed by applying sealant from a dual chamber syringe with mixing tip and then re-inflated
  • the lung was evaluated for leakage by submersion in water Evaluation of the lung for air leakage did not indicate any to be present, indicating the efficacy of the sealant
  • a sealant was prepared comprising 30% albumin and 0 2% chitosan and a crosslinker solution containing 7 5% heat-processed glutaraldehyde and 20% dextran
  • the process followed for making the sealant was as described above
  • the lungs of an anaesthetized pig were exposed and deflated Following this step, a portion of the upper lobe of the lung was transected and the cut site of the deflated lung was sealed by applying sealant from a dual chamber syringe with mixing tip and then re-mflated
  • the lung was evaluated for leakage by submersion in water Evaluation of the lung for air leakage did not indicate any to be present, indicating the efficacy of the sealant
  • a sealant was prepared comprising 38% albumin and 0 2% chitosan and a crosslinker solution containing 4.4% heat-processed glutaraldehyde and 20% dextran
  • the process followed for making the sealant was as described above
  • the lungs of an anaesthetized pig were exposed and deflated Following this step, a portion of the upper lobe of the lung was transected and the cut site of the deflated lung was sealed by applying sealant from a dual chamber syringe with mixing tip and then re-mflated
  • the lung was evaluated for leakage by submersion m water Evaluation of the lung for air leakage did not indicate any to be present, indicating the efficacy of the sealant
  • the composition successfully sealed the lung indicating the efficacy of the sealant B.
  • a sealant composition comprising 45% albumin and a crosslinker solution containing 7 5% heat-processed glutaraldehyde and 3% carboxymethyl cellulose, was prepared The process followed for making the sealant was as described above The visceral pleura surface of an anesthetized pig lung was exposed The lung was then inflated insuring positive air pressure to physiological conditions Sealant then was applied to the anterior portion of the pleural surface using a delivery catheter Following 20 seconds, a section of chest wall containing parietal pleura was placed directly on top of the anterior portion of the visceral pleura The sealant was then allowed to set for one minute The adhesion of the two pleural surfaces was then evaluated by lifting up the chest wall (parietal pleura) only If the two pleura surfaces were still attached then the adhesive was considered effective The two pleural surfaces adhered together with the use of this composition Example 2
  • a sealant composition comprising 40% albumin and 0 2% chitosan and a crosslinker solution containing 4% heat-processed glutaraldehyde and 20% dextran, was prepared The process followed for making the sealant was as described above The visceral pleura surface of an anesthetized pig lung was exposed The lung was then inflated insuring positive air pressure to physiological conditions Sealant then was applied to the anterior portion of the pleural surface using a delivery catheter Following 20 seconds, a section of chest wall containing parietal pleura was placed directly on top of the anterior portion of the visceral pleura The sealant was then allowed to set for one minute The adhesion of the two pleural surfaces was then evaluated by lifting up the chest wall (parietal pleura) only If the two pleura surfaces were still attached then the adhesive was considered effective The two pleural surfaces adhered together with the use of this composition.
  • a sealant composition comprising 38% albumin and 0 2% chitosan and a crosslinker solution containing 7 5% heat-processed glutaraldehyde and 20% dextran, was prepared The process followed for making the sealant was as described above The visceral pleura surface of an anesthetized pig lung was exposed The lung was then inflated insuring positive air pressure to physiological conditions Sealant then was applied to the anterior portion of the pleural surface using a delivery catheter Following 20 seconds, a section of chest wall containing parietal pleura was placed directly on top of the anterior portion of the visceral pleura The sealant was then allowed to set for one minute The adhesion of the two pleural surfaces was then evaluated by lifting up the chest wall (parietal pleura) only If the two pleura surfaces were still attached then the adhesive was considered effective The two pleural surfaces adhered together with the use of this composition
  • a sealant composition comprising 40% albumin and 1 0% chitosan and a crosslinker solution containing 3 5% heat-processed glutaraldehyde and 20% glycerol, was prepared The arteries of an anesthetized, anticoagulated rabbit were exposed The artery of the left side was punctured with a catheter.
  • a sealant comprising 38% albumin and 0 2% chitosan and a crosslinker solution containing 7 0% heat- processed glutaraldehyde and 6% povidone, was prepared The arteries of an anesthetized, anticoagulated rabbit were exposed The artery of the left side was punctured with a catheter Following removal of the catheter, the hole was closed using the sealant Alternately, the artery of the right side was transected, and an anastomosis was created using a suture.
  • a sealant comprising 35% albumin and 1 0% chitosan and a crosslinker solution containing 4 4% heat- processed glutaraldehyde and 20% dextran, was prepared The arteries of an anesthetized, anticoagulated rabbit were exposed The artery of the left side was punctured with a catheter Following removal of the catheter, the hole was closed using the sealant Alternately, the artery of the right side was transected, and an anastomosis was created using a suture An umbilical tape was partially looped around the vessel proximal to the surgery site to momentarily reduce blood flow Sealant was then applied to the puncture site using a dual chamber syringe with mixing tip Following two minutes, the pressure was released to expose the repair to the full systohc/diastolic pressure of the carotid artery No leakage was found to be present from the wound site Sealant was also applied to the partially leaking anastomotic site of the right side of the expe
  • a sealant composition comprising 40% albumin and 5% Polyethylene glycol and a crosslinker solution containing 7 5% heat-processed glutaraldehyde and, was prepared The process followed for making the sealant was as described above Following a craniotomy, the exposed dura of a bovine model was incised Incision of the dura resulted in retraction of the tissue The retracted tissue was drawn together, again using temporary sutures such that the incised edges were opposed to one another Sealant was applied with dual chamber syringe with mixing tip over the incision wound and the suture stays were released The opposing edges of the incision wound remained aligned with one another, all three sealant compositions demonstrated adequate tenacity to resist the retractive forces of the dura The head was lowered placing additional stress on the suture and the site was observed for failure of the sealant to hold the edges together. No failures were observed.
  • Example 2 Example 2
  • a sealant composition comprising 38% albumin and 0 2% hyaluronic acid and a crosslinker solution containing 4 4% heat-processed glutaraldehyde and 20% dextran, was prepared The process followed for making the sealant was as described above Following a craniotomy, the exposed dura of a bovine model was incised Incision of the dura resulted m retraction of the tissue The retracted tissue was drawn together, again using temporary sutures such that the incised edges were opposed to one another Sealant was applied with dual chamber syringe with mixing tip over the incision wound and the suture stays were released The opposing edges of the incision wound remained aligned with one another, all three sealant compositions demonstrated adequate tenacity to resist the retractive forces of the dura. The head was lowered placing additional stress on the suture and the site was observed for failure of the sealant to hold the edges together. No failures were observed.
  • a sealant composition comprising 35% albumin and 1.0% hyaluronic acid and a crosslinker solution containing 4.4% heat-processed glutaraldehyde and 15% dextran, was prepared. The process followed for making the sealant was as described above. Following a craniotomy, the exposed dura of a bovine model was incised.
  • An adhesive composition is for use as a tissue/bioptsy site marker is prepared using two solutions; a protein solution of purified porcine serum albumin (PSA) with chitosan (Solution "A"), a hemostatic agent, and a solution of processed glutaraldehyde (PGA) with dextran, an excipient (as a thickener) (Solution "B”).
  • PSA porcine serum albumin
  • PGA processed glutaraldehyde
  • B an excipient
  • the device is provided sterile, ready for use, in pre-filled syringes packaged in single peel Tyvek-polyethylene pouches to provide up to
  • Each solution (approximately 1.0 mL) is filled into a separate chamber of a dual-chamber syringe that is sealed with a dual-opening cap at the tip and with "piston" stopper-seals at the end of each chamber.
  • Each filled and sealed dual-chamber syringe is packaged with a separately provided Vent Adjustment Device (VAD) mixing tip, dual-rod plunger in a sealed single Tyvek-polyethylene peel pouch that is terminally sterilized by radiation.
  • VAD Vent Adjustment Device
  • the "piston" stopper-seals are designed to accommodate the ends of the dual-rod plunger that is inserted into the end of each chamber and advanced to engage the "piston" stopper seals.
  • the VAD mixing tip is designed to be attached to the tip of the dual-chamber syringe (in place of the cap) and both: (1) mechanically purges the dead-space air from the hub and mixing element segment of the mixing tip through its vent feature; (2) helps to ensure a 1:1 mixture of the two solutions; and (3) mixes the two solutions as they are dispensed.
  • the adhesive composition is prepared for use by removing the cap at the tip of the dual-chamber syringe
  • a needle may be attached to the end of the VAD mixing tip.
  • the needle can be a commercially available standard injection needle, biopsy needle, or introducer etc., that have a standard luer lock hub of ⁇ 21 gauge (> 0.76 mm ID).
  • the needle can be a 21-18G standard or steerable Seeker Biopsy Needle(s).
  • the solutions are mixed and dispensed by applying smooth and continuous pressure to the end of the plunger until the desired amount of the adhesive composition is delivered to the tissue/surgical location.
  • the adhesive composition polymerizes into a solid within 10-50 seconds after it is mixed/dispensed.
  • the processed glutaraldehyde in the adhesive composition will also cross-link to the tissue site ensuring that the marker remains at the placement site.
  • the polymerized marker is slowly resorbable by hydrolysis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Materials For Medical Uses (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition adhésive et une méthode associée. L'invention concerne en particulier une composition adhésive contenant un composant protéique et un composant aldéhyde, ce dernier contenant également un agent épaississant. La composition selon l'invention est utilisée pour adhérer à un tissu dans diverses applications. Cette composition peut être utilisée pour marquer un emplacement à l'intérieur du corps humain, l'emplacement d'une tumeur par exemple.
PCT/US2007/078932 2006-09-20 2007-09-19 Compositions adhesives pour tissu et methodes associees Ceased WO2008036763A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07842812.5A EP2064300A4 (fr) 2006-09-20 2007-09-19 Compositions adhesives pour tissu et methodes associees
US12/602,468 US20100297218A1 (en) 2006-09-20 2007-09-19 Tissue adhesive compositions and methods thereof
JP2009529372A JP2010504410A (ja) 2006-09-20 2007-09-19 組織接着剤組成物およびその方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82624206P 2006-09-20 2006-09-20
US60/826,242 2006-09-20

Publications (2)

Publication Number Publication Date
WO2008036763A2 true WO2008036763A2 (fr) 2008-03-27
WO2008036763A3 WO2008036763A3 (fr) 2008-05-08

Family

ID=39201248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/078932 Ceased WO2008036763A2 (fr) 2006-09-20 2007-09-19 Compositions adhesives pour tissu et methodes associees

Country Status (4)

Country Link
US (1) US20100297218A1 (fr)
EP (1) EP2064300A4 (fr)
JP (1) JP2010504410A (fr)
WO (1) WO2008036763A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7549984B2 (en) 2004-06-16 2009-06-23 Pneumrx, Inc. Method of compressing a portion of a lung
WO2010135352A1 (fr) * 2009-05-18 2010-11-25 Pneumrx, Inc. Modification de section transversale durant le déploiement d'un dispositif allongé de réduction du volume pulmonaire
US20110091389A1 (en) * 2009-10-16 2011-04-21 Ezekiel Kruglick Particles with radiation activated adhesive
US8142455B2 (en) 2006-03-13 2012-03-27 Pneumrx, Inc. Delivery of minimally invasive lung volume reduction devices
US8632605B2 (en) 2008-09-12 2014-01-21 Pneumrx, Inc. Elongated lung volume reduction devices, methods, and systems
US8740921B2 (en) 2006-03-13 2014-06-03 Pneumrx, Inc. Lung volume reduction devices, methods, and systems
US9185432B2 (en) 2008-11-04 2015-11-10 Koninklijke Philips N.V. Method and system for encoding a 3D image signal, encoded 3D image signal, method and system for decoding a 3D image signal
US9402633B2 (en) 2006-03-13 2016-08-02 Pneumrx, Inc. Torque alleviating intra-airway lung volume reduction compressive implant structures
US10390838B1 (en) 2014-08-20 2019-08-27 Pneumrx, Inc. Tuned strength chronic obstructive pulmonary disease treatment
US10537334B2 (en) 2013-10-25 2020-01-21 Pneumrx, Inc. Genetically-associated chronic obstructive pulmonary disease treatment

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9386990B2 (en) * 2008-03-19 2016-07-12 University Of Florida Research Foundation, Inc. Nerve repair with a hydrogel and adhesive
US8221994B2 (en) * 2009-09-30 2012-07-17 Cilag Gmbh International Adhesive composition for use in an immunosensor
JP2012045358A (ja) 2010-08-25 2012-03-08 Terumo Corp 肺気腫の治療剤
US9539077B1 (en) 2011-12-05 2017-01-10 Daniel A. Dopps Method for alternatively resisting and permitting menstrual flow
US20150342610A1 (en) * 2014-05-29 2015-12-03 Pulmonx Corporation Medical devices and methods for lung volume reduction
US10299916B2 (en) * 2016-01-07 2019-05-28 Medtronic Vascular, Inc. Bioprosthetic tissue repair and reinforcement
BR112019006145A2 (pt) 2016-09-30 2019-06-18 Pneumrx Inc recipientes para dispositivos médicos
BR112019006173A2 (pt) 2016-09-30 2019-06-18 Pneumrx Inc fio guia
US10993919B2 (en) 2016-10-04 2021-05-04 University Of Florida Research Foundation, Inc. Chondroprotective nanoparticles for the treatment of osteoarthritis
CN107126578A (zh) * 2017-04-21 2017-09-05 常州市蓝勖化工有限公司 一种医用粘合剂的制备方法
CN109971403A (zh) * 2019-02-28 2019-07-05 常州五荣化工有限公司 一种大豆蛋白基双组分木材胶粘剂的制备方法

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3301692A (en) * 1966-02-14 1967-01-31 Wilson & Co Inc Process of treating proteins and the product thereof
US3438374A (en) * 1966-02-28 1969-04-15 Us Health Education & Welfare Method of bonding tissue surfaces and controlling hemorrhaging thereof using a tissue adhesive and hemostatic composition
US3722599A (en) * 1967-12-01 1973-03-27 Minnesota Mining & Mfg Fluorocyanoacrylates
US3527841A (en) * 1968-04-10 1970-09-08 Eastman Kodak Co Alpha-cyanoacrylate adhesive compositions
US3559652A (en) * 1968-08-05 1971-02-02 Minnesota Mining & Mfg Method of adhesively repairing body tissue with alkoxyalkyl 2-cyanoacrylate
JPS554118B2 (fr) * 1973-08-29 1980-01-29
GB2041377B (en) * 1979-01-22 1983-09-28 Woodroof Lab Inc Bio compatible and blood compatible materials and methods
US4725279A (en) * 1979-01-22 1988-02-16 Sterling Drug Inc. Bio compatible and blood compatible materials and methods
US4442655A (en) * 1981-06-25 1984-04-17 Serapharm Michael Stroetmann Fibrinogen-containing dry preparation, manufacture and use thereof
US4820302A (en) * 1982-04-22 1989-04-11 Sterling Drug Inc. Bio compatible and blood compatible materials and methods
CA1196863A (fr) * 1983-06-08 1985-11-19 Mattheus F.A. Goosen Composes d'insuline injectable a liberation lente
GB8322002D0 (en) * 1983-08-16 1983-09-21 Atomic Energy Authority Uk Gauging apparatus
US4983392A (en) * 1983-11-14 1991-01-08 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
US5231112A (en) * 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US4911713A (en) * 1986-03-26 1990-03-27 Sauvage Lester R Method of making vascular prosthesis by perfusion
JPS6323670A (ja) * 1986-04-25 1988-01-30 バイオ−ポリマ−ズ　インコ−ポレ−テツド 接着・被覆組成物とその使用方法
IL78826A (en) * 1986-05-19 1991-05-12 Yissum Res Dev Co Precursor composition for the preparation of a biodegradable implant for the sustained release of an active material and such implants prepared therefrom
GB8628398D0 (en) * 1986-11-27 1986-12-31 Central Blood Lab Authority Pharmaceutically-active conjugates
US4795136A (en) * 1987-01-21 1989-01-03 Haefner Joseph F Apparatus for erecting forms
US5011686A (en) * 1987-09-21 1991-04-30 Creative Biomolecules, Inc. Thrombus specific conjugates
US5139527A (en) * 1987-12-17 1992-08-18 Immuno Aktiengesellschaft Biologic absorbable implant material for filling and closing soft tissue cavities and method of its preparation
US5290552A (en) * 1988-05-02 1994-03-01 Matrix Pharmaceutical, Inc./Project Hear Surgical adhesive material
US5008245A (en) * 1988-10-27 1991-04-16 University Of Kentucky Research Foundation Novel peptidyl carbamate inhibitors of the enzyme elastase
US5024829A (en) * 1988-11-21 1991-06-18 Centocor, Inc. Method of imaging coronary thrombi
US5663299A (en) * 1989-02-23 1997-09-02 Center For Blood Research, Inc. Human monocyte elastase inhibitor
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US20030113369A1 (en) * 1991-01-16 2003-06-19 Martin Francis J. Liposomes with enhanced circulation time and method of treatment
US5219895A (en) * 1991-01-29 1993-06-15 Autogenesis Technologies, Inc. Collagen-based adhesives and sealants and methods of preparation and use thereof
US5385606A (en) * 1992-07-06 1995-01-31 Kowanko; Nicholas Adhesive composition and method
CN1091315A (zh) * 1992-10-08 1994-08-31 E·R·斯奎布父子公司 血纤维蛋白封闭剂组合物及其使用方法
AU5665694A (en) * 1992-11-04 1994-05-24 Denver Biomaterials Inc. Apparatus for removal of pleural effusion fluid
US5290683A (en) * 1992-11-19 1994-03-01 Yedy Israel Rapid analysis of ethanol in body fluids
US5328687A (en) * 1993-03-31 1994-07-12 Tri-Point Medical L.P. Biocompatible monomer and polymer compositions
US5312331A (en) * 1993-04-15 1994-05-17 Knoepfler Dennis J Method and apparatus for talc pleurodesis
US5549904A (en) * 1993-06-03 1996-08-27 Orthogene, Inc. Biological adhesive composition and method of promoting adhesion between tissue surfaces
ATE241340T1 (de) * 1994-02-17 2003-06-15 New York Blood Ct Inc Biologische bioadhäsive präparate, die fibrinkleber und liposomen enthalten, verfahren für ihre herstellung und verwendung
US20030109866A1 (en) * 1994-06-24 2003-06-12 Neomend, Inc. Vascular sealing device with microwave antenna
US5817303A (en) * 1995-05-05 1998-10-06 Protein Polymer Technologies, Inc. Bonding together tissue with adhesive containing polyfunctional crosslinking agent and protein polymer
US6565842B1 (en) * 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
US5928611A (en) * 1995-06-07 1999-07-27 Closure Medical Corporation Impregnated applicator tip
US6833408B2 (en) * 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
US6375926B1 (en) * 1996-09-16 2002-04-23 Amersham International Plc Labelled elastase inhibitors
JPH1099425A (ja) * 1996-09-26 1998-04-21 Hiroaki Nomori 生体適合接着剤
AU4907897A (en) * 1996-10-11 1998-05-11 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
EP0964690B1 (fr) * 1996-10-15 2003-07-09 The Liposome Company, Inc. Conjugues de peptide-lipide, liposomes et apport de medicaments par des liposomes
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
US6010714A (en) * 1996-11-22 2000-01-04 Closure Medical Corporation Non-thermogenic heat dissipating biomedical adhesive compositions
DE19721691A1 (de) * 1997-05-23 1998-11-26 Basf Ag Klebstoffe auf Basis einer wässrigen Polymerdispersion, Verfahren zu ihrer Herstellung und ihre Verwendung
US7005124B2 (en) * 1997-07-07 2006-02-28 Dendritic Nanotechnologies, Inc. Dendritic-antineoplastic drug delivery system
TWI222441B (en) * 1997-11-26 2004-10-21 Dimensional Pharm Inc Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
JP4603157B2 (ja) * 1998-03-13 2010-12-22 ザ バーナム インスティチュート 種々の選択された器官または組織にホーミングする分子
US6514522B2 (en) * 1998-04-08 2003-02-04 Chondros, Inc. Polymer constructs
AU4682999A (en) * 1998-06-16 2000-01-05 Human Genome Sciences, Inc. 94 human secreted proteins
US6512023B1 (en) * 1998-06-18 2003-01-28 Closure Medical Corporation Stabilized monomer adhesive compositions
US20020022588A1 (en) * 1998-06-23 2002-02-21 James Wilkie Methods and compositions for sealing tissue leaks
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7279001B2 (en) * 1998-11-06 2007-10-09 Neomend, Inc. Systems, methods, and compositions for achieving closure of vascular puncture sites
JP2000288079A (ja) * 1999-04-07 2000-10-17 Toyobo Co Ltd 生体組織用接着剤
DE60032003T2 (de) * 1999-09-15 2007-06-06 Aradigm Corp., Hayward Porenstrukturen zur niederdruckaerosolisierung
EP1214057B1 (fr) * 1999-09-15 2009-10-28 CryoLife, Inc. Composition de revetement vasculaire
US6183498B1 (en) * 1999-09-20 2001-02-06 Devore Dale P. Methods and products for sealing a fluid leak in a tissue
US6726718B1 (en) * 1999-12-13 2004-04-27 St. Jude Medical, Inc. Medical articles prepared for cell adhesion
WO2001045761A1 (fr) * 1999-12-22 2001-06-28 Surgical Sealants, Inc. Methodes et compositions permettant de bloquer les fuites dans des tissus
WO2001055390A1 (fr) * 2000-01-28 2001-08-02 Human Genome Sciences, Inc. Polynucleotides, polypeptides, et anticorps serpiniques humains
WO2001056548A2 (fr) * 2000-02-04 2001-08-09 Lipoxen Technologies Limited Liposomes
US20030070683A1 (en) * 2000-03-04 2003-04-17 Deem Mark E. Methods and devices for use in performing pulmonary procedures
AU2001264817A1 (en) * 2000-05-23 2001-12-17 Exhale Therapeutics, Inc. Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans
US20040120979A1 (en) * 2000-06-02 2004-06-24 Roessler Blake J. Delivery systems comprising biocompatible and bioerodable membranes
WO2001096538A2 (fr) * 2000-06-13 2001-12-20 Bayer Aktiengesellschaft Regulation de la serine protease transmembranaire humaine
US20020086842A1 (en) * 2000-06-26 2002-07-04 Christian Plank Method for transfecting cells using a magnetic field
JP2004510830A (ja) * 2000-10-11 2004-04-08 ターゲサム・インコーポレーテッド 標的化された治療用薬剤
AU2001295765B2 (en) * 2000-10-23 2006-02-23 Tissuemed Limited Self-adhesive hydratable matrix for topical therapeutic use
US6685626B2 (en) * 2001-02-02 2004-02-03 Regeneration Technologies, Inc. Compositions, devices, methods, and kits for induction of adhesions
AU2002256989A1 (en) * 2001-02-05 2002-09-24 Bristol-Myers Squibb Company Polynucleotides encoding a metalloprotease, mp-1
WO2002072788A2 (fr) * 2001-03-14 2002-09-19 Centocor, Inc. Proteines provenant de l'immunoglobuline associees a la bronchopneumopathie chronique obstructive, compositions, procedes et utilisations
JP4511071B2 (ja) * 2001-03-29 2010-07-28 日本碍子株式会社 ハニカム構造体及びそのアッセンブリ
US20040086896A1 (en) * 2001-04-19 2004-05-06 Julie Carman Polynucleotides and polypeptides associated with the NF-kB pathway
US6552172B2 (en) * 2001-08-30 2003-04-22 Habto Biotech, Inc. Fibrin nanoparticles and uses thereof
ATE366597T1 (de) * 2001-10-11 2007-08-15 Emphasys Medical Inc Bronchiale durchflussvorrichtung
US20040063813A1 (en) * 2001-12-10 2004-04-01 Bin Wu Powder coating compositions containing reactive nanoparticles
US6701640B2 (en) * 2002-01-14 2004-03-09 Wolverine World Wide, Inc. Self draining shoe
US20040126777A1 (en) * 2002-01-28 2004-07-01 Bhatt Ramesh Rajani Lp mammalian proteins; related reagents
US7329414B2 (en) * 2002-05-03 2008-02-12 Biopsy Sciences, Llc Biodegradable polymer for marking tissue and sealing tracts
WO2003105676A2 (fr) * 2002-06-17 2003-12-24 Bistech, Inc. Compositions et procedes pour reduire le volume pulmonaire
US20040121362A1 (en) * 2002-06-20 2004-06-24 Whitney Gena S. Identification and modulation of a G-protein coupled receptor (GPCR), RAI-3, associated with chronic obstructive pulmonary disease (COPD) and NF-kappaB and E-selectin regulation
US20040052850A1 (en) * 2002-09-13 2004-03-18 Kemal Schankereli Proteinaceous hemostatic tissue sealant
AU2003257180A1 (en) * 2002-08-06 2004-02-23 Matrix Medical, Llc Biocompatible phase invertable proteinaceous compostions and methods for making and using the same
US7371345B2 (en) * 2002-12-23 2008-05-13 Closure Medical Corporation Sterilization of medical adhesive kits
US20050004599A1 (en) * 2003-06-30 2005-01-06 Mcnally-Heintzelman Karen M. Non-light activated adhesive composite, system, and methods of use thereof
US7129210B2 (en) * 2003-07-23 2006-10-31 Covalent Medical, Inc. Tissue adhesive sealant
US7678767B2 (en) * 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US20050288684A1 (en) * 2004-06-16 2005-12-29 Aronson Nathan A Method of reducing collateral flow in a portion of a lung
US7553810B2 (en) * 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
JP5113519B2 (ja) * 2004-07-08 2013-01-09 ヌームアールエックス・インコーポレーテッド 胸膜滲出の治療装置，治療方法及び材料
US7766891B2 (en) * 2004-07-08 2010-08-03 Pneumrx, Inc. Lung device with sealing features
JP2006051121A (ja) * 2004-08-10 2006-02-23 National Institute For Materials Science アルブミンと生体低分子誘導体から構成される生体内分解吸収性粘着性医用材料
US20060058867A1 (en) * 2004-09-15 2006-03-16 Thistle Robert C Elastomeric radiopaque adhesive composite and prosthesis
EP1816945B1 (fr) * 2004-11-23 2019-08-21 PneumRx, Inc. Dispositif orientable destine a acceder a un site cible
JP2007277344A (ja) * 2006-04-04 2007-10-25 Toyobo Co Ltd 生体吸収性接着剤組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2064300A4 *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7549984B2 (en) 2004-06-16 2009-06-23 Pneumrx, Inc. Method of compressing a portion of a lung
US8932310B2 (en) 2006-03-13 2015-01-13 Pneumrx, Inc. Minimally invasive lung volume reduction devices, methods, and systems
US9474533B2 (en) 2006-03-13 2016-10-25 Pneumrx, Inc. Cross-sectional modification during deployment of an elongate lung volume reduction device
US8142455B2 (en) 2006-03-13 2012-03-27 Pneumrx, Inc. Delivery of minimally invasive lung volume reduction devices
US8157823B2 (en) 2006-03-13 2012-04-17 Pneumrx, Inc. Lung volume reduction devices, methods, and systems
US8157837B2 (en) 2006-03-13 2012-04-17 Pneumrx, Inc. Minimally invasive lung volume reduction device and method
US10226257B2 (en) 2006-03-13 2019-03-12 Pneumrx, Inc. Lung volume reduction devices, methods, and systems
US8282660B2 (en) 2006-03-13 2012-10-09 Pneumrx, Inc. Minimally invasive lung volume reduction devices, methods, and systems
US10188397B2 (en) 2006-03-13 2019-01-29 Pneumrx, Inc. Torque alleviating intra-airway lung volume reduction compressive implant structures
US8668707B2 (en) 2006-03-13 2014-03-11 Pneumrx, Inc. Minimally invasive lung volume reduction devices, methods, and systems
US10188398B2 (en) 2006-03-13 2019-01-29 Pneumrx, Inc. Cross-sectional modification during deployment of an elongate lung volume reduction device
US8740921B2 (en) 2006-03-13 2014-06-03 Pneumrx, Inc. Lung volume reduction devices, methods, and systems
US8888800B2 (en) 2006-03-13 2014-11-18 Pneumrx, Inc. Lung volume reduction devices, methods, and systems
US9402632B2 (en) 2006-03-13 2016-08-02 Pneumrx, Inc. Lung volume reduction devices, methods, and systems
US9402971B2 (en) 2006-03-13 2016-08-02 Pneumrx, Inc. Minimally invasive lung volume reduction devices, methods, and systems
US9402633B2 (en) 2006-03-13 2016-08-02 Pneumrx, Inc. Torque alleviating intra-airway lung volume reduction compressive implant structures
US9782558B2 (en) 2006-03-13 2017-10-10 Pneumrx, Inc. Minimally invasive lung volume reduction devices, methods, and systems
US9192403B2 (en) 2008-09-12 2015-11-24 Pneumrx, Inc. Elongated lung volume reduction devices, methods, and systems
US10058331B2 (en) 2008-09-12 2018-08-28 Pneumrx, Inc. Enhanced efficacy lung volume reduction devices, methods, and systems
US10285707B2 (en) 2008-09-12 2019-05-14 Pneumrx, Inc. Enhanced efficacy lung volume reduction devices, methods, and systems
US8632605B2 (en) 2008-09-12 2014-01-21 Pneumrx, Inc. Elongated lung volume reduction devices, methods, and systems
US9173669B2 (en) 2008-09-12 2015-11-03 Pneumrx, Inc. Enhanced efficacy lung volume reduction devices, methods, and systems
US9185432B2 (en) 2008-11-04 2015-11-10 Koninklijke Philips N.V. Method and system for encoding a 3D image signal, encoded 3D image signal, method and system for decoding a 3D image signal
CN102573700A (zh) * 2009-05-18 2012-07-11 纽姆克斯股份有限公司 细长的肺减容装置在部署过程中的横截面变化
US8721734B2 (en) 2009-05-18 2014-05-13 Pneumrx, Inc. Cross-sectional modification during deployment of an elongate lung volume reduction device
CN102573700B (zh) * 2009-05-18 2014-12-17 纽姆克斯股份有限公司 细长的肺减容装置在部署过程中的横截面变化
WO2010135352A1 (fr) * 2009-05-18 2010-11-25 Pneumrx, Inc. Modification de section transversale durant le déploiement d'un dispositif allongé de réduction du volume pulmonaire
US20110091389A1 (en) * 2009-10-16 2011-04-21 Ezekiel Kruglick Particles with radiation activated adhesive
US9682156B2 (en) * 2009-10-16 2017-06-20 Empire Technology Development Llc Particles with radiation activated adhesive
US10537334B2 (en) 2013-10-25 2020-01-21 Pneumrx, Inc. Genetically-associated chronic obstructive pulmonary disease treatment
US10390838B1 (en) 2014-08-20 2019-08-27 Pneumrx, Inc. Tuned strength chronic obstructive pulmonary disease treatment

Also Published As

Publication number Publication date
EP2064300A2 (fr) 2009-06-03
US20100297218A1 (en) 2010-11-25
WO2008036763A3 (fr) 2008-05-08
EP2064300A4 (fr) 2013-05-22
JP2010504410A (ja) 2010-02-12

Similar Documents

Publication Publication Date Title
US20100297218A1 (en) Tissue adhesive compositions and methods thereof
Jain et al. Recent developments and clinical applications of surgical glues: An overview
JP3735677B2 (ja) 酸化分解で変性させた非架橋コラーゲンをベースとする外科用接着性組成物
US20020015724A1 (en) Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing
US20030032143A1 (en) Collagen type I and type III compositions for use as an adhesive and sealant
WO2000009018A9 (fr) Compositions hemostatiques a base de collagene de type i et de type iii, a utiliser en tant que produit de scellement vasculaire et pansement
CN109200331B (zh) 一种肺部封合医用凝胶及其制备方法与应用
EP4545104A1 (fr) Timbre biologique résorbable, auto-adhésif, son procédé de préparation et son utilisation
US8173722B2 (en) Adhesive compositions for use in surgical therapy
WO2024000861A1 (fr) Maillage biologique absorbable auto-adhésif à deux composants peg, son procédé de préparation et utilisation associée
JP2001511431A (ja) Ｉ型およびｉｉｉ型コラーゲン接着剤組成物
EP2185207B1 (fr) Combinaison de collage de tissus biologiques
US9474825B2 (en) Methods for sealing fluid leaks in lung tissue
EP4450095A1 (fr) Adhésif médical pour tissu, son procédé de préparation et son utilisation
Kawai et al. Sealing effect of cross-linked gelatin glue in the rat lung air leak model
CN118576750B (zh) 一种生物合成可注射粘合剂及其制备方法与在肠瘘修复中的应用
Karmaker Development and characterization of autologous fibrin glue augmented with biocompatible polymers
CN210904261U (zh) 一种自粘性止血人工硬膜修补片
Lee et al. Injectable Click Fibroin Bioadhesive Derived from Spider Silk for Accelerating Wound Closure and Healing Bone Fracture. Materials 2022, 15, 5269
CN119386244A (zh) 外泌体负载热敏感可逆粘附凝胶及其制备方法
CN119909220A (zh) 一种生物胶水
CN119405870A (zh) 一种可注射型组织粘合剂及其应用
CN114533944A (zh) 一种基于天然化合物的弹性体组织密封胶及其制备方法
CN118139646A (zh) 一种鲵皮肤分泌物水解液及其制备方法和应用
MXPA00001013A (en) Collagen type i and type iii adhesive compositions

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2007842812

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009529372

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12602468

Country of ref document: US